Regeneron Pharmaceuticals Inc. buy Jefferies Financial Group Inc.
Summary
This prediction is currently active. With a performance of 33.41% the BUY prediction by Jefferies_Financial_ is a big success. A total of €2.76 was paid as dividends for this prediction. This prediction currently runs until 27.08.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.524% | 2.524% |
| iShares Core DAX® | 2,57 % | 5,33 % |
| iShares Nasdaq 100 | 4,86 % | 0,45 % |
| iShares Nikkei 225® | 5,59 % | -0,59 % |
| iShares S&P 500 | 3,25 % | 2,50 % |
Comments by Jefferies_Financial_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Jefferies_Financial_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
28.11.23
28.11.24
29.11.24

